Last updated: February 27, 2026
What is NDC 70677-1020?
NDC 70677-1020 is a prescription drug identified by the National Drug Code (NDC) number. Based on available data, this code corresponds to Vigabatrin (Sabril), used primarily for epilepsy treatment. Its clinical use restricts it to specific patient populations due to safety concerns, such as potential vision loss.
Market Overview
Incidence and Demand
- Epilepsy patient population in the U.S.: Approximately 3.4 million individuals (CDC, 2022).
- Refractory epilepsy patients: About 30% do not respond well to first-line therapies.
- Vigabatrin's niche: Approved specifically for infantile spasms and refractory complex partial seizures.
Competition
| Drug Name |
Indication |
Market Share (2022) |
Price Range (per unit) |
| Vigabatrin (Sabril) |
Infantile spasms, complex partial seizures |
N/A |
$1,200 - $1,800 |
| Topiramate |
General epilepsy, migraine prevention |
Dominates epilepsy market |
$0.70 - $1.00 per capsule |
| Levetiracetam |
Broad epilepsy indication |
Significant market share |
$1.20 - $1.50 per capsule |
Vigabatrin's sales are limited relative to broader-spectrum antiepileptics due to safety concerns, which restrict its use and distribution.
Regulatory and Utilization Trends
- FDA Approval: For infantile spasms and refractory epilepsy.
- Black Box Warning: Vision loss risk limits prescribing.
- Market dynamics: Preference for newer drugs with fewer safety concerns has suppressed growth potential.
Price Trajectory and Projection Analysis
Current Pricing
- Wholesale acquisition cost (WAC): Approximately $1,200 to $1,800 per 500 mg tablet (varies by supplier and region).
- Average retail price: $1,500 per unit.
Influencing Factors
- Safety concerns: Maintain high pricing due to limited competition.
- Prescribing restrictions: Reduce volume and thus hinder price erosion.
- Supply chain constraints: Few manufacturers produce Vigabatrin, maintaining pricing stability.
Future Price Projections (Next 5 Years)
| Year |
Expected Price Range (per unit) |
Key Drivers |
| 2023 |
$1,400 - $1,800 |
Limited competition; ongoing safety concerns persist |
| 2024-2025 |
$1,350 - $1,750 |
Slight pressure from generics or biosimilar development |
| 2026-2027 |
$1,300 - $1,700 |
Introduction of alternative therapies; regulatory updates |
| 2028-2030 |
$1,250 - $1,650 |
Potential for price stabilization, given restricted use context |
Scenario Considerations
- Regulatory changes: Any indication expansion or safety loosening could reduce prices.
- Generic or biosimilar entry: Highly unlikely within this timeframe due to the drug’s safety profile and manufacturing complexity.
Market Risks and Opportunities
Risks
- Safety profile limitations: Risks of vision loss constrains usage and uptake.
- Emergence of new therapies: Gene therapy, neuromodulation, or new antiepileptics could replace Vigabatrin.
- Regulatory tightening: Any changes in prescribing guidelines could further limit market access.
Opportunities
- Niche market dominance: For refractory infantile spasms, where alternatives are limited.
- Extension of indications: Potential for expanded approval could increase use and price.
- Combination therapies: Developing fixed-dose combinations could open new markets.
Key Takeaways
- NDC 70677-1020 (Vigabatrin) operates in a limited market segment, constrained by safety concerns.
- Current prices hover between $1,200 and $1,800 per unit.
- Future price erosion is unlikely due to poor competition, safety restrictions, and manufacturing barriers.
- Market growth prospects depend heavily on regulatory changes and the development of alternative treatments.
- The drug retains a niche but stable position mainly for refractory epilepsy and infantile spasms.
FAQs
Q1: What factors most influence Vigabatrin’s pricing stability?
Limited competition, safety restrictions, and manufacturing complexity predominantly support price stability.
Q2: Are there any upcoming patent expirations?
Vigabatrin lacks recent patent protections, but market penetration remains limited by safety concerns and prescribing restrictions.
Q3: What clinical developments could impact its market?
Approval of new therapies with better safety profiles or expanded indications could reduce demand and prices.
Q4: How does the competition compare in terms of efficacy?
While alternatives like topiramate and levetiracetam are widely used, they are not indicated for infantile spasms, which restricts Vigabatrin’s niche.
Q5: What is the likelihood of generic entry?
Generic versions are unlikely soon due to the drug’s safety profile and complex manufacturing, maintaining current pricing levels.
Sources
[1] Centers for Disease Control and Prevention (CDC). (2022). Epilepsy Statistics.
[2] U.S. Food and Drug Administration (FDA). (2022). Vigabatrin (Sabril) drug label.
[3] IQVIA. (2022). U.S. Pharmaceutical Market Data.
